Stay updated with breaking news from Darryl Sampey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Frederick, Maryland (PRWEB) July 10, 2023 -- BioFactura, Inc. today announced that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo
Frederick, Maryland (PRWEB) October 14, 2022 -- BioFactura Inc. has announced today the completion of the pivotal pharmacokinetic comparability clinical trial
Frederick, MD (PRWEB) July 15, 2022 -- BioFactura today announced its second contract option activation of $15.9 million from the Biomedical Advanced Research
Biosimilars uptake is increasing in the U.S. but strong market headwinds are limiting market share and impeding stronger competition and lower prices.
BioFactura announces initiation of Phase I study of BFI-751, a Stelara® (ustekinumab) biosimilar Share Article BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. BioFactura "Given the prevalence and impact of autoimmune diseases on people across the globe, it is exciting to be taking the next step for...